Home › NDC Lookup › RxCUI directory › RxCUI 603162

Ramelteon 8 MG Oral Tablet [Rozerem] — RxCUI 603162

RxNorm drug concept · Semantic branded drug
RxCUI 603162 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI603162
Official nameRamelteon 8 MG Oral Tablet [Rozerem]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asRozerem 8 MG Oral Tablet
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)16,237 prescriptions · 14 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ramelteon: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats insomnia when your main trouble is falling asleep. It works on melatonin receptors in the brain that help regulate your sleep-wake cycle.
  • Take one tablet by mouth within 30 minutes of going to bed. Don't take it with or right after a high-fat meal, since that changes how it's absorbed. Follow your prescriber's direct...
  • The more common ones are sleepiness, dizziness, tiredness, nausea and worsening insomnia. Avoid driving or other risky tasks after your dose. Do only what you need to get ready for...
  • Get emergency help for swelling of the tongue, throat or face, or trouble breathing. Call your doctor if you do things like drive or cook while asleep, see things that aren't there...
📖 Read our full Ramelteon guide →

🕸️ Concept Web — How Ramelteon 8 MG Oral Tablet [Rozerem] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Ramelteon 8 MG Oral Tablet [Rozerem] RxCUI 603162

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ramelteon 596205
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Rozerem 603159
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ramelteon Oral Tablet 577347
    • Ramelteon Oral Product 1157899
    • Ramelteon Pill 1157900
    • Ramelteon Oral Tablet [Rozerem] 603161
    • Rozerem Oral Product 1182585
    • Rozerem Pill 1182586
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Ramelteon 8 MG Oral Tablet SCD · 577348
  • Ramelteon 8 MG SCDC · 577346
  • Ramelteon Oral Tablet SCDF · 577347
  • Ramelteon Oral Product SCDG · 1157899
  • Ramelteon Pill SCDG · 1157900

Brand-Name Concepts

  • Ramelteon 8 MG [Rozerem] SBDC · 603160
  • Ramelteon Oral Tablet [Rozerem] SBDF · 603161
  • Rozerem Oral Product SBDG · 1182585
  • Rozerem Pill SBDG · 1182586
  • Rozerem BN · 603159

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 603162 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
64764-0805-10 100 TABLET, FILM COATED in 1 BOTTLE (64764-805-10) Rozerem Takeda Pharmaceuticals America, Inc. 2005-07-22
64764-0805-30 30 TABLET, FILM COATED in 1 BOTTLE (64764-805-30) Rozerem Takeda Pharmaceuticals America, Inc. 2005-07-22
Observed labelers: Takeda Pharmaceuticals America, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$12.4424
Range $12.4424–$12.4424 · middle 50% $12.4424–$12.4424 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.